Validation of a method for quantifying enzalutamide and its major metabolites in human plasma by LC-MS/MS

Bioanalysis

Volumn 6, Issue 6, 2014, Pages 737-744

  Bennett, Daniel ^a   Gibbons, Jacqueline A ^b   Mol, Roelof ^c   Ohtsu, Yoshiaki ^d   Williard, Clark ^a  

^a SYNEOS HEALTH   (United States)

^b Medivation Inc   (United States)

^c Astellas Pharma Global Development   (Netherlands)

^d ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLIC ACID; DRUG METABOLITE; ENZALUTAMIDE; N DESMETHYL ENZALUTAMIDE; UNCLASSIFIED DRUG; PHENYLTHIOHYDANTOIN;

ACCURACY; ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; EXTRACTION; HUMAN; PLASMA; QUALITY CONTROL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY ANALYSIS; SEPARATION TECHNIQUE; VALIDATION PROCESS; ANALOGS AND DERIVATIVES; BLOOD; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PROCEDURES; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

CHROMATOGRAPHY, LIQUID; HUMANS; MALE; MASS SPECTROMETRY; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84898718727     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.325     Document Type: Article

References (7)

1. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928), 787-790 (2009).
2. Scher HI, Fizazi K, Saad F et al. AFFIRM investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187-1197 (2012).
3. Scher HI, Beer TM, Higano CS et al. Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of enzalutamide in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375(9724), 1437-1446 (2010).
4. US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Guidance for Industry Bioanalytical Method Validation. Center for Drug Evaluation and Research, Rockville, MD, USA (2001).
5. Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24(10), 1962-1973 (2007).
6. Hughes NC, Bajaj N, Fan J, Wong EY. Assessing the matrix effects of hemolyzed samples in bioanalysis. Bioanalysis 1(6), 1057-1066 (2009).
7. Lowes S, Jersey J, Shoup R et al. Recommendations on: internal standard criteria, stability, incurred sample reanalysis and recent 483s by the Global CRO Council for Bioanalysis. Bioanalysis 3(12), 1323-1332 (2011).